Evidence map›Paper›PMID 20631072›Full record

ArticleCancer research2010

Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.

Kara Mitchell, Kimberly B Svenson, Whitney M Longmate, Katerina Gkirtzimanaki, Rafal Sadej, Xianhui Wang, Jihe Zhao, Aristides G Eliopoulos, Fedor Berditchevski, C Michael Dipersio

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. The epidermal integrin-mediated secretome regulates the skin microenvironment during tumorigenesis and repair.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Frontiers in oncology · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Kara MitchellCenter for Cell Biology & Cancer Research, Albany Medical College, Albany, New York 12208-3479, USA.
Kimberly B Svenson
Whitney M Longmate
Katerina Gkirtzimanaki
Rafal Sadej
Xianhui Wang
Jihe Zhao
Aristides G Eliopoulos
Fedor Berditchevski
C Michael Dipersio
Albany Medical Center Hospital · USUniversity of Birmingham · GBCancer Research UK · GBUniversity of Crete · GR

Funding

Regulation of MMP-9 mRNA stability and tumor growth by alpha3 beta1 integrinR01CA129637 · NCI · ALBANY MEDICAL COLLEGE · PI DIPERSIO, C. MICHAEL · 2008 to 2020
$3.3M
TISSUE REMODELING AND CARDIOVASCULAR DISEASET32HL007194 · NHLBI · ALBANY MEDICAL COLLEGE · PI MC KEOWN-LONGO, PAULA J · 1985 to 2006
$2.9M
KLF8 Regulation of EMT Tumor MetastasisR01CA132977 · NCI · UNIVERSITY OF CENTRAL FLORIDA · PI ZHAO, JIHE · 2009 to 2014
$1.3M
Cancer Research UK A5705Cancer Research UK C1322/A5705NCI NIH HHS R01 CA129637NCI NIH HHS R01CA129637NCI NIH HHS R01 CA132977NCI NIH HHS R01CA132977NHLBI NIH HHS T32 HL007194NHLBI NIH HHS T32-HL-07194
6 · The paper itself

Abstract

Integrin receptors for cell adhesion to extracellular matrix have important roles in promoting tumor growth and progression. Integrin alpha3beta1 is highly expressed in breast cancer cells in which it is thought to promote invasion and metastasis; however, its roles in regulating malignant tumor cell behavior remain unclear. In the current study, we used short-hairpin RNA (shRNA) to show that suppression of alpha3beta1 in a human breast cancer cell line, MDA-MB-231, leads to decreased tumorigenicity, reduced invasiveness, and decreased production of factors that stimulate endothelial cell migration. Real-time PCR revealed that suppression of alpha3beta1 caused a dramatic reduction in expression of the cyclooxygenase-2 (COX-2) gene, which is frequently overexpressed in breast cancers and has been exploited as a therapeutic target. Decreased COX-2 was accompanied by reduced prostaglandin E2 (PGE(2)), a major prostanoid produced downstream of COX-2 and an important effector of COX-2 signaling. shRNA-mediated suppression of COX-2 showed that it has a role in tumor cell invasion and cross-talk to endothelial cells. Furthermore, treatment with PGE(2) restored these functions in alpha3beta1-deficient MDA-MB-231 cells. These findings identify a role for alpha3beta1 in regulating two properties of tumor cells that facilitate cancer progression: invasiveness and ability to stimulate endothelial cells. They also reveal a novel role for COX-2 as a downstream effector of alpha3beta1 in tumor cells, thereby identifying alpha3beta1 as a potential therapeutic target to inhibit breast cancer.

Indexed as

AnimalsBreast NeoplasmsCell CommunicationCell Line, TumorCyclooxygenase 2Endothelial CellsFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansIntegrin alpha3beta1MiceMice, NudeNeoplasm InvasivenessRNA, MessengerRNA, Small InterferingCyclooxygenase 2Integrin alpha3beta1RNA, MessengerRNA, Small Interfering

Identifiers

PMID20631072
PMCPMC2913124
OpenAlexW2088929132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.